AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05980104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
Study NCT05846425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nose-breathing training
Description: 13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
Study NCT05846425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth-breathing training
Description: 13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
Study NCT04703608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 0.3-0.4mg/Kg daily for 3 days.
Study NCT04703608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP
Description: Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
Study NCT04703608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-identical placebo
Study NCT04703608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-identical placebo
Study NCT05774223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)-active
Description: Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
Study NCT05774223 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)-sham
Description: Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
Study NCT05734001 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROTEM Tests
Description: This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg
Study NCT05734001 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Haemostatic Tests
Description: To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: > 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
Study NCT04048707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Intravenous
Study NCT04048707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Pill
Study NCT04048707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Subcutaneous
Study NCT04048707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: Intravenous suspension
Study NCT04048707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin solution
Description: Intravenous suspension
Study NCT06049355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT06395753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4228
Description: Administered as IM injection.
Study NCT06691984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluritamig
Description: Short-term IV infusion
Study NCT06691984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Oral tablets
Study NCT06691984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral tablets
Study NCT06691984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: IV infusion
Study NCT05763550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
Study NCT05153421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All'InCath CBC 035M Balloon Dilatation Catheter
Description: Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
Study NCT06702007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHaRT-A
Description: Adaptation of the Harm Reduction Treatment for Alcohol (HaRT-A) into a digital telehealth platform facilitating harm reduction treatment via patient-provider video sessions (eHaRT-A). eHaRT-A will include the three treatment components from the efficacious HaRT-A. eHaRT-A will be delivered during one-on-one sessions through video conferencing with interactive features (i.e., personalized feedback tracked over time and screen sharing).
Study NCT06699810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
Study NCT06699810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
Study NCT05763550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 40mg BID
Description: HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
Study NCT05763550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
Study NCT06163170 — intervention group
Intervention type: DRUG
Intervention: Nivolumab +/- ipilimumab
Description: Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
Study NCT06163170 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
Study NCT06703398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC101 TIL
Description: Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for resection
Study NCT04792164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra sound guided nerve block
Description: Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
Study NCT04792164 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual infiltration
Description: Usual infiltration by lidocaine before open inguinal hernia repair.
Study NCT06703398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
Description: monotherapy or combination of dacarbazine, temozolomide, paclitaxel, platinum or cisplatun, and the chemotherapy's dosage could refer to the drug label or the relevant treatment guideline, the final decision is up to investigator
Study NCT06695845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered by intravenous (IV) infusion
Study NCT06706674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone high dose
Description: Lumateperone administered orally once daily
Study NCT06706674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone low dose
Description: Lumateperone administered orally once daily
Study NCT06706674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo administered orally once daily
Study NCT06712641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin + narrow spectrum betalactam
Description: Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
Study NCT06712641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Empirical therapy for suspected community-acquired sepsis with cefotaxime
Study NCT06712641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam
Description: Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
Study NCT06706752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shengbai Oral Formula
Description: Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.
Study NCT06706752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Inactive placebo will be taken by mouth three times per day for 14 days.
Study NCT06709456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided pleural drainage
Description: Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter. Contralateral and repeated drainage conducted as specified during ICU stay until day 90.
Study NCT06707233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: The patients will receive 1-2 sessions of SIRT.
Study NCT06144489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tart Cherry
Description: Tart cherry supplementation in two doses
Study NCT06144489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group
Study NCT06470750 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06713707 — intervention group
Intervention type: OTHER
Intervention: Manuel dexterity
Description: Individuals who meet the inclusion criteria will be evaluated for manual dexterity using 9-HPT, and JTHFT.
Study NCT06713707 — intervention group
Intervention type: OTHER
Intervention: Manual Dexterity (only MMDT)
Description: Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
Study NCT06688058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V540D
Description: Experimental vaccine and adjuvant administered via intramuscular (IM) injection
Study NCT06688058 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®9
Description: Suspension administered via IM injection
Study NCT06703203 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 26-Valent pneumococcal conjugate vaccine
Description: As an experimental group. The active ingredient of 26-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 26 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
Study NCT06703203 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 23-Valent pneumococcal polysaccharide vaccine
Description: As a control group. The effective ingredients of 23-valent pneumococcal polysaccharide vaccine are 23 serotypes of pneumococcal capsular polysaccharides. Administer one dose of 0.5mL each time.
Study NCT06703203 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13-Valent pneumococcal conjugate vaccine
Description: As a control group. The active ingredient of 13-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 13 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
Study NCT06715371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE)
Description: Transthoracic echocardiography (TTE) is a non-invasive imaging technique performed by placing an ultrasound transducer on the chest to obtain detailed heart images. TTE is conducted preoperatively on awake patients within two weeks prior to cardiac surgery, following ASE chamber quantification guidelines.~Transesophageal echocardiography (TEE) is an invasive imaging technique where an ultrasound transducer is placed in the esophagus, providing closer and clearer images of the heart. TEE is performed intraoperatively under general anesthesia as part of routine care.
Study NCT06717295 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DiNanoQ: A multi-cancer early detection (MCED) blood test
Description: Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.
Study NCT06717295 — intervention group
Intervention type: OTHER
Intervention: DiNanoTrack: Therapeutic Response Monitoring Blood Test
Description: Procedures:~Blood Sample Collection: Participants will have blood samples drawn at three time points:~Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.~Sample Analysis:~Platelet and Immune Cell Isolation:~Platelets: Extracted from each blood sample to continue monitoring RNA profiles.~Immune Cells: Separated from the blood samples to analyse immune response to therapy.~RNA Analysis:~Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.~Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.~Data Correlation:~Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance.
Study NCT06722430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral capsule
Study NCT06722430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ)
Description: Oral capsule
Study NCT06722417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral capsules
Study NCT06717347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab vedotin
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Biosimilar
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: IV infusion
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral administration
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral administration
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral administration
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral administration
Study NCT06717347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: IV infusion
Study NCT06726343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
Study NCT06726343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Fetal Monitoring Device
Description: Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
Study NCT06705712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of activity trackers and motivational conversations to enhance focus on physical activity among women trying to conceive.
Description: All participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) which will be connected with an application, Fitrockr. Data from the devices will be linked to data from the Snartforældre-questionnaires. The participants are asked to wear the tracker 24/7 during preconception and during the first trimester of their pregnancy if they conceive within 12 months.~Participants will receive information material and be asked to set goals for their PA level. To follow-up on the goal setting, they will receive two phone calls, where the conversations will be inspired by motivational interviewing.
Study NCT06721572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEA
Description: Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.
Study NCT06727812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6208
Description: HRS-6208.
Study NCT06730126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soquelitinib
Description: Soquelitinib is an ITK inhibitor in clinical development for treating relapsed/refractory T-cell lymphoma.
Study NCT06725732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery
Study NCT06725732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
Study NCT06710249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum/SPC flakes
Description: Egg yolk powder and specially processed cereals
Study NCT06720675 — intervention group
Intervention type: PROCEDURE
Intervention: Hypothermic Oxygented Perfusion
Description: HOPE start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid (cold Belzer MPS solution) during back-table preparation. Hepatic perfusion was performed through the vein leads to a pressure of 3-5 mmHg. Organ were treated with continuous HOPE until transplant and the perfusion was continuously monitored and data downloaded in a USB memory.
Study NCT06720675 — intervention group
Intervention type: PROCEDURE
Intervention: Static Cold Storage
Description: Liver grafts are stored in sterile organ bags with cold Belzer or Celsior solution and kept in ice at 4°C.
Study NCT06720909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The standard 8-week MBSR program will be led by certified MBSR instructors from the UCSD Center for Mindfulness. The program content will consist of a variety of mindfulness and meditative techniques, such as sitting meditation, body scans, and mindful yoga. Participants will engage in weekly sessions via Zoom, participation in group discussions, and honing their other mindfulness skills. Throughout the program, participants will be instructed to commit to a daily mindfulness meditation practice lasting approximately 45 minutes, at least 6 days a week.